Dana-Farber Cancer Institute
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Dana-Farber Cancer Institute sits in the top decile of US sponsors by registered trial count (#42 of 15,742 sponsors by registered trial count).
Dana-Farber Cancer Institute: 781 sponsored US clinical trials, 112 recruiting.
Dana-Farber Cancer Institute sponsors 781 registered US clinical trials on ClinicalTrials.gov, 112 of them currently recruiting, and 449 completed. 15 of these trials are in Phase 3-4 (later-stage) and 492 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Breast Cancer, with 53 trials.
Top-decile sponsor footprint
Dana-Farber Cancer Institute ranks in the top decile of sponsors by registered trial count (#42 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
449 of 537 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (83.6%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
781 total, page 9 of 16
Study of Ibrutinib in Patients With Symptomatic, Previously Untreated Waldenstrom's Macroglobulinemia, and Impact on Tumor Genomic Evolution Using Whole Genome Sequencing
NCT02604511
Phase II Study of Efficacy and Safety of Lenalidomide, Subcutaneous Bortezomib and Dexamethasone Therapy for Newly Diagnosed Multiple Myeloma
NCT02441686
CBTI-CS: A Novel Cognitive-Behavioral Treatment for Insomnia in Cancer Survivors
NCT02756390
MLN0128 in Recurrent/Metastatic Merkel Cell Carcinoma
NCT02514824
Study of Phosphatidylinositol-3-kinase (PI3K) Inhibitor Idelalisib (GS-1101) in Waldenström Macroglobulinemia
NCT02439138
The Incidence of Adjacent Synchronous Ipsilateral Infiltrating Carcinoma and/or DCIS in Patients Diagnosed With Intraductal Papilloma Without Atypia or Flat Epithelial Atypia by Core Needle Biopsy
NCT02489617
Harnessing the Effect of an Open-Label Placebo on Fatigue in Cancer Survivors
NCT02452710
Trial of Ponatinib in Patients With Bevacizumab-Refractory Glioblastoma
NCT02478164
A Study of Palbociclib in Combination With Bazedoxifene in Hormone Receptor Positive Breast Cancer
NCT02448771
Incorporating MR Imaging Into Prostate Radiotherapy Treatment Planning
NCT02470910
A Phase I/II Study of MLN0128 in Metastatic Anaplastic Thyroid Cancer and Incurably Poorly Differentiated or Radioidodine Refractory Differentiated Thyroid Cancer
NCT02244463
Improving Informed Consent for Palliative Chemotherapy
NCT02282722
A Study to Optimize Care for Lung Cancer Patients Undergoing Video-Assisted Thoracoscopic Surgery (VATS)
NCT02502695
Pilot Study of Zirconium-89 Bevacizumab Positron Emission Tomography for Imaging Angiogenesis in Patients With Inflammatory Breast Carcinoma Receiving Preoperative Chemotherapy
NCT01894451
Study of Bortezomib,Lenalidomide,Dexamethasone & Elotuzumab in Newly Diagnosed MM
NCT02375555
Bone Mineral Density Status in Pediatric and Adolescent Survivors of Childhood Cancer With History of Bone Fracture
NCT02355340
Detection of Tumor Associated Cell-free DNA in Peritoneal Fluid Obtained by Culdocentesis
NCT02441140
Pembrolizumab After ASCT for Hodgkin Lymphoma, DLBCL and T-NHL
NCT02362997
Exploratory Study of Radium-223 and VEGF-Targeted Therapy in Patients With Metastatic Renal Cell Carcinoma and Bone Mets
NCT02406521
Trial of Ixazomib, Dexamethasone and Rituximab in Patients With Untreated Waldenstrom's Macroglobulinemia
NCT02400437
Pembrolizumab +/- Bevacizumab for Recurrent GBM
NCT02337491
Patient-Centered Care for the Older Adult With Hematologic Malignancy
NCT02359838
Study of Individual Adult and Pediatric Patient Dose-escalated Interleukin-2 Therapy for Refractory Chronic GVHD
NCT02318082
Image-guided Cryoablation of Head, Neck and Spine Tumors
NCT02085941
Evaluating Mass Spectrometry And Intraoperative MRI In The Advanced Multimodality Image Guided Operating Suite (Amigo) In Breast-Conserving Therapy
NCT02335671
A Phase II Trial of Low-Dose Interleukin-2 (IL-2) Added to Extra-Corporeal Photopheresis for Steroid-Refractory cGVHD
NCT02340676
Phase II Trial of Natalizumab + Prednisone for Initial Therapy of Acute GI GVHD
NCT02176031
E-PRISM: Phase II Trial of Elotuzumab Lenalidomide and Dexamethasone in High-Risk Smoldering Multiple Myeloma
NCT02279394
A Phase 2 Clinical Trial of Rituxan and B-Glucan PGG in Relapsed Indolent Non-Hodgkin Lymphoma
NCT02086175
A Phase I/Ib Safety and Efficacy Study of the PI3K-delta Inhibitor TGR-1202 and Ibrutinib in Patients With CLL or MCL
NCT02268851
Cabozantinib +/- Trastuzumab In Breast Cancer Patients w/ Brain Metastases
NCT02260531
Sexual Therapy and Rehabilitation After Treatment for Ovarian Cancer (START-OC): A Pilot Intervention
NCT02287519
Enzalutamide/Leuprolide +/- Abiraterone/Pred in Prostate
NCT02268175
Impact of Cerebellar Mass Resection on Pain Processing
NCT02261649
Phase Ib Study of BKM120 With Cisplatin and XRT in High Risk Locally Advanced Squamous Cell Cancer of Head and Neck
NCT02113878
Everolimus for Cancer With TSC1 or TSC2 Mutation
NCT02201212
Crizotinib in Combination With Enzalutamide in Metastatic Castration-resistant Prostate Cancer
NCT02207504
Personal Web Page In Clinical Trial Participant Education
NCT03887091
Phase Ib Study of SUnitinib Alternating With REgorafenib in Patients With Metastatic and/or Unresectable GIST
NCT02164240
Study of Omalizumab as Adjuvant Therapy in Chemotherapy Desensitization
NCT02118987
An Open Label Phase II Trial of Topical Sirolimus for the Treatment of Refractory Oral Chronic Graft-versus-Host-Disease
NCT02123966
A Pilot Study of Acupuncture for Chemotherapy-induced Peripheral Neuropathy in Breast Cancer Patients
NCT02129686
A Study of Idelalisib (GS1101, CAL101) + Ofatumumab in Previously Untreated CLL/SLL
NCT02135133
Naltrexone RCT for Treatment-Emergent Fatigue in Patients Receiving Radiation Therapy for Breast Cancer
NCT02137252
Cisplatin vs Paclitaxel for Triple Negative Breast Cancer
NCT01982448
Feasibility Study of Low Level Light Therapy for Prevention of Oropharyngeal Mucositis in Pediatric Transplants Patients
NCT02119897
Enzalutamide + External Beam Rt For Prostate
NCT02028988
Ruxolitinib W/ Preop Chemo For Triple Negative Inflammatory Brca
NCT02041429
Cabozantinib in Recurrent/Metastatic Merkel Cell Carcinoma
NCT02036476
Study of Abiraterone Acetate Without Exogenous Glucocorticoids in Men With Castration-resistant Prostate Cancer
NCT02025010
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 181 |
| Phase 2 | 311 |
| Phase 3 | 14 |
| Phase 4 | 1 |
Therapeutic Areas
What is open in the Dana-Farber Cancer Institute pipeline
112 recruiting of 781 indexed (14% open); 449 completed (57%).
Phase mix: 15 late (III/IV) vs 492 early (I/II) (early-phase heavy).
Top condition: Breast Cancer (53 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Dana-Farber Cancer Institute: open-pipeline peers nationwide
Peers matched on 781 registered trials and 14% open enrollment, not the therapeutic-area sidebar.
Dana-Farber Cancer Institute sits at or above the median trial volume and below the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 781 trials (± recruiting share)
- University of California, San Diego · 775 trials · 18% recruiting
- University of Chicago · 796 trials · 20% recruiting
- Medical University of South Carolina · 755 trials · 19% recruiting
- University of Utah · 818 trials · 17% recruiting
Sponsors near 14% open enrollment (± trial volume)
- The Cleveland Clinic · 14% recruiting · 688 trials
- Academic and Community Cancer Research United · 14% recruiting · 42 trials
- Adaptive Biotechnologies · 14% recruiting · 7 trials
- AgelessRx · 14% recruiting · 7 trials
Related
What to do with this Dana-Farber Cancer Institute page
781 registered trials is a research-attention snapshot, not an endorsement of Dana-Farber Cancer Institute or any single study.
- 112 of Dana-Farber Cancer Institute's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Breast Cancer is the condition Dana-Farber Cancer Institute studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Breast Cancer trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Dana-Farber Cancer Institute pipeline card: 781 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.